The International Council on Infertility Information Dissemination, Inc

Corona Funk

Illustration of snow falling and gingerbread houses, and masked snowman and gingerbread character

Corona Christmas and Chanukah --


A Holiday Time Like no Other in our Time. By Helen Adrienne, LCSW, BCD

I've always been a self-starter.  I never lacked for some project to dive into, whether by obligation or by interest.  Until now. 

I've already knitted an afghan blanket for everyone I know and love who can still fog up a mirror.  Yeah, there's the book-club book, staring at me from the coffee table.  Of course, if you wanna eat, there's always the obligatory trip to the supermarket, and from the supermarket to the stove.  That is unless ennui prevails, and then the effort goes into deciding on and dialing for take-out if that's an option in your neck of woods.  And not until the threat of running out of underwear becomes real do I override the ennui and take off for the laundry room. 

So what happened to Self-Starter Me?  And maybe you?

I remember hearing about the pandemic of 1918.  Who woulda thunk that we'd be living through a pandemic in this "advanced" age of miracle medicine in the 'first world' US of A?  But here we are, at the mercy of a microscopic enemy.

Much of life goes on, albeit virtually, which is a boon.  Yet, if you're like me, there's nothing like the real thing.  For instance, I'll be participating in the annual but this year virtual Evolution Conference for mental health practitioners.  Missing will be the meet-and-greet so enjoyed by me and my colleagues who in years past have harkened from all corners of the world. 

What substitutes have been mandated in your world?    

I greet my husband every day with the comment, "Good morning.  It's another Dayday."  While it is true that Suspended Animation shall eventually pass, meanwhile, it's best to be thankful for what we've got: an on-line substitute for the real thing, with colleagues, friends and relatives.    

So.  What would give you a sense that you will survive this pandemic?  Do any of us need to add to, or polish up our coping skills at this time like no other?  There's a saying, "Move a muscle, change a mood."  Perhaps we should invent a Funky Corona Funk dance.  It could become a craze that relieves the craziness you might be feeling.  Imagine -- Zoom parties where everyone is wearing a mask and 'funky-ing' around! 

The holidays can be a mixed bag.  This year, if we respect the request to hunker down with our "pod", the holidays could feel like a wedding without a bride.  Given the socially requested limitations, what could happen if we called upon our creative juices?  How can we make the best of the reality right down to watching a virtual nutcracker, leaving cookies and milk for a Santa who will have to zoom down the chimney via Zoom, or maybe a virtual game of Dreidel? 

Fortunately, at least we have the United States Postal Service.   

I sincerely hope that anyone reading this is healthy, either having dodged the corona bullet or having safely recovered.  

Helen Adrienne, LCSW, BCD


Webinar: The Trauma of Toxic Stress During the Pandemic: What You Can Do

Download Handouts Here


Toxic stress has the potential to change brain chemistry, brain anatomy, and even gene expression in children. Toxic stress also affects adults and can weaken the architecture of the immune response. The toxic stress response is believed to play a role in the pathophysiology of depressive disorders, behavioral dysregulation, PTSD (Post Traumatic Stress Disorder), and even psychosis.

There is a significant difference between normal stress and toxic stress.  Where normal and positive stress is an essential part of healthy development, toxic stress occurs when we experience strong, frequent, and/or long-lasting difficult events — such the pandemic.

Come join us on June 1, 2020, at 7 PM. to meet and chat with Amy Peterson, LCSW. Amy is experienced in facilitating individual, group, and family therapy. She has a Bachelor of Fine Arts in Theatre and a master's degree in clinical social work. Amy uses a playful approach, particularly when working with younger clients. Amy is passionate about education and has extensive experience presenting to clients and professionals at local and national venues. Her therapeutic approach is attachment focused, trauma-informed, strengths-based, and family systems-oriented. Amy is an optimist and believes everyone possesses the power to discover, develop, and express full potential living. 


A helpful article on Developmental Trauma for educators




Aytu BioScience Demonstrates Expanded Clinical Utility of MiOXSYS™ for Assessing Oxidative Stress as a Marker for Male Infertility with New Study

ENGLEWOOD, Colo., May 10, 2016 /PRNewswire/ -- Aytu BioScience, Inc. (OTCQX: AYTU), a specialty pharmaceutical company focused on global commercialization of novel products in the field of urology, today announced new clinical findings that further validate and expand the potential utility of its MiOXSYS System as an advanced tool for assessing oxidative stress in human semen, which is broadly implicated as a major cause of male infertility. The results demonstrate that the level of oxidative stress reported by MiOXSYS from semen samples that had been frozen and thawed did not differ significantly from readings taken before freezing. This is significant, as it eliminates the need for fresh sampling and enables MiOXSYS to be used by regional or national reference laboratories that can receive and store shipped frozen samples, in addition to rapid, on-site testing by local urologists' offices, hospital, and fertility clinical laboratories.

The poster, titled, "Validation of oxidation-reduction potential in fresh and frozen semen samples with MiOXSYS™ System," was presented yesterday by the study's principal investigator, Ashok Agarwal, Ph.D., Director of the Glickman Urological & Kidney Institute's Andrology Center at Cleveland Clinic and Director of the American Center for Reproductive Medicine, at the 111th American Urological Society Annual Meeting in San Diego, CA.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, stated, "These latest clinical findings add robustness to our MiOXSYS System, which we've already demonstrated to be a uniquely dynamic tool for assessing oxidative stress levels in semen as it relates to male infertility, offering substantial clinical benefit beyond the complicated and highly time-sensitive methods used today.  Being able to use MiOXSYS to analyze frozen then thawed semen samples is another key differentiator for our product that further reduces the burden and increases efficiency for routine oxidative stress testing. It also enables Aytu to potentially engage with large laboratory networks to offer MiOXSYS testing through their current frozen sample collection channels. As we continue to pursue FDA clearance of MiOXSYS in the U.S. by conducting larger, multicenter studies, these commercial implications may add significantly greater value to the product upon potential launch."

In the study, semen samples were collected from 20 healthy normospermic men and oxidative stress was induced using varying concentrations of cumene hydroperoxide (CH). Using MiOXSYS, the differences in oxidative stress readings between pre-freeze and post-thaw samples were not significant, either for controls or samples exposed to CH, indicating that MiOXSYS can measure real-time oxidative stress levels accurately in both fresh and frozen semen samples. Furthermore, MiOXSYS was sensitive enough to detect CH-induced changes when compared with control (Mean ± standard error of mean) in oxidative stress as measured by static ORP (millivolts (mV)/106 sperm/mL) both prior to freezing (0.52 + 0.24; 95 % confidence interval (0.03, 1.01); p=0.04) and after post-thaw change (0.75 + 0.31; 95 % confidence interval (0.10, 1.39); p=.025), as an indicator of strong test performance under both conditions. There was also a dose-dependent decrease in sperm motility in samples upon exposure to CH, confirming a decline in sperm quality as a result of oxidative stress. 

The MiOXSYS System received CE Marking in the European Union in January 2016 and approval from Health Canada in March 2016, and it is currently being commercialized in Europe and the Middle East. Aytu has established and will continue to seek additional partnerships with prominent hospitals, academic centers, and other early MiOXSYS users in order to develop these markets.

About Aytu BioScience, Inc. 
Aytu BioScience is a commercial-stage specialty pharmaceutical company focused on global commercialization of novel products in the field of urology. The company currently markets two products: ProstaScint® (capromab pendetide), the only FDA-approved imaging agent specific to prostate cancer, and Primsol® (trimethoprim hydrochloride), the only FDA-approved trimethoprim-only oral solution for urinary tract infections. Aytu recently acquired exclusive U.S. rights to Natesto®, the first and only FDA-approved nasal formulation of testosterone for men with hypogonadism (low testosterone, or "Low T"), which the company plans to launch in July 2016. Additionally, Aytu is developing MiOXSYS™, a novel, rapid semen analysis system with the potential to become a standard of care for the diagnosis and management of male infertility caused by oxidative stress. MiOXSYS is commercialized outside the U.S. where it is a CE Marked, Health Canada cleared product, and Aytu is conducting U.S.-based clinical trials in pursuit of 510k de novo medical device clearance by the FDA. Aytu's strategy is to continue building its portfolio of revenue-generating urology products, leveraging its focused commercial team and expertise to build leading brands within well-established markets.

Investors & Media: 
Tiberend Strategic Advisors, Inc. 
Joshua Drumm, Ph.D.:; (212) 375-2664  
Janine McCargo:; (646) 604-5150

Forward Looking Statement 
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, including statements regarding our anticipated future clinical and regulatory events, future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. Forward looking statements are generally written in the future tense and/or are preceded by words such as "may," "will," "should," "forecast," "could," "expect," "suggest," "believe," "estimate," "continue," "anticipate," "intend," "plan," or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: risks related to our planned launch and commercialization of Natesto and the integration of Natesto into our existing operations; our plans for product growth, expansion and acquisition; the anticipated start dates, durations and completion dates, as well as the potential future results, of our ongoing and future clinical trials; risks relating to gaining market acceptance of our products; obtaining reimbursement by third-party payors; the potential future commercialization of our product candidates; the anticipated designs of our future clinical trials; anticipated future regulatory submissions and events; our anticipated future cash position; and future events under our current and potential future collaborations. We also refer you to the risks described in "Risk Factors" in Part I, Item 1A of Aytu BioScience, Inc.'s Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.


SOURCE Aytu BioScience, Inc.